10x Gene-Expression Patent Trial Nixed as Curio Deal Nears (1)

A federal judge canceled next week’s jury trial over claims Curio Bioscience Inc.’s tissue-mapping kits infringe five spatial-gene-expression patents Prognosys Biosciences Inc. exclusively licenses to 10x Genomics Inc.

Curio and two other Takara Bio Inc. subsidiaries “have reached an agreement in principle” with 10x and Prognosys that would end the case, according to a stipulation and order Judge Maryellen Noreika issued May 8 in the US District Court for the District of Delaware. If the parties don’t file for dismissal by June 8, they’ll file a joint status report on that date, Noreika said.

The judge vacated all deadlines, including ...